Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib | Zendy

Pascal Hammel | Zendy; F. Huguet | Zendy; JeanLuc Van Laethem | Zendy; David Goldstein | Zendy; Bengt Glimelius | Zendy; Pascal Artru | Zendy; Ivan Borbath | Zendy; Olivier Bouché | Zendy; Jenny Shan | Zendy; Thierry André | Zendy; Laurent Mineur | Zendy; Benoist Chibaudel | Zendy; Franck Bonnetain | Zendy; Christophe Louvet | Zendy

Open Access

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

Author(s) -

Pascal Hammel,

F. Huguet,

JeanLuc Van Laethem,

David Goldstein,

Bengt Glimelius,

Pascal Artru,

Ivan Borbath,

Olivier Bouché,

Jenny Shan,

Thierry André,

Laurent Mineur,

Benoist Chibaudel,

Franck Bonnetain,

Christophe Louvet

Publication year - 2016

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2016.4324

Subject(s) - medicine , gemcitabine , erlotinib , chemoradiotherapy , capecitabine , oncology , randomization , pancreatic cancer , erlotinib hydrochloride , interim analysis , chemotherapy , induction chemotherapy , randomized controlled trial , cancer , surgery , epidermal growth factor receptor , colorectal cancer

In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of erlotinib is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research